Vitamin D Pilot Study in Patients With Multiple Sclerosis

This study has been completed.
Information provided by (Responsible Party):
University of Wisconsin, Madison Identifier:
First received: December 8, 2010
Last updated: October 1, 2015
Last verified: December 2010
Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Drug: 19 nor vitamin d
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Official Title: Vitamin D Pilot Study in Patients With Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • MRI Measure of new active lesions, observation vs. treatment

Study Start Date: February 1998
Study Completion Date: June 2000
Primary Completion Date: February 2000 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 19 nor vitamin d Drug: 19 nor vitamin d


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • relapsing remitting MS

Exclusion Criteria:

  • MRI contraindicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01257958

United States, Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
  More Information

Responsible Party: University of Wisconsin, Madison Identifier: NCT01257958     History of Changes
Other Study ID Numbers: HSC #97-676-311 
Study First Received: December 8, 2010
Last Updated: October 1, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Wisconsin, Madison:
Vitamin D, 19 nor Vitamin D, Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Vitamin D
Bone Density Conservation Agents
Growth Substances
Physiological Effects of Drugs processed this record on May 26, 2016